Orchard Therapeutics plc [NASDAQ: ORTX] traded at a low on 07/02/21, posting a -3.26 loss after which it closed the day’ session at $4.15. The company report on July 1, 2021 that Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema.
Highlights the broader potential of Orchard’s ex vivo HSC gene therapy platform approach in new and larger indications.
Reinforces Pharming’s commitment to the HAE community and utilizes its relevant clinical expertise and global commercialization infrastructure.
The results of the trading session contributed to over 747334 shares changing hands. Over the past one week, the price volatility of Orchard Therapeutics plc stands at 7.20% while the volatility over the past one month is 5.05%.
The market cap for ORTX stock reached $517.21 million, with 114.83 million shares outstanding and 81.79 million shares in the current float. Compared to the average trading volume of 468.93K shares, ORTX reached a trading volume of 747334 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Orchard Therapeutics plc [ORTX]?
JP Morgan have made an estimate for Orchard Therapeutics plc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 02, 2021. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on March 02, 2021, representing the official price target for Orchard Therapeutics plc stock. Previously, the target price had yet another raise to $16, while Cantor Fitzgerald analysts kept a Overweight rating on ORTX stock.
The Average True Range (ATR) for Orchard Therapeutics plc is set at 0.24, with the Price to Sales ratio for ORTX stock in the period of the last 12 months amounting to 198.93. The Price to Book ratio for the last quarter was 1.61, with the Price to Cash per share for the same quarter was set at 2.39.
How has ORTX stock performed recently?
Orchard Therapeutics plc [ORTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.54. With this latest performance, ORTX shares dropped by -20.65% in over the last four-week period, additionally sinking by -3.94% over the last 6 months – not to mention a drop of -30.02% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ORTX stock in for the last two-week period is set at 25.35, with the RSI for the last a single of trading hit 19.78, and the three-weeks RSI is set at 29.97 for Orchard Therapeutics plc [ORTX]. The present Moving Average for the last 50 days of trading for this stock 5.24, while it was recorded at 4.44 for the last single week of trading, and 5.63 for the last 200 days.
Orchard Therapeutics plc [ORTX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Orchard Therapeutics plc [ORTX] shares currently have an operating margin of -6863.51 and a Gross Margin at -10.25. Orchard Therapeutics plc’s Net Margin is presently recorded at -5856.61.
Return on Total Capital for ORTX is now -61.71, given the latest momentum, and Return on Invested Capital for the company is -54.50. Return on Equity for this stock declined to -64.13, with Return on Assets sitting at -45.03. When it comes to the capital structure of this company, Orchard Therapeutics plc [ORTX] has a Total Debt to Total Equity ratio set at 32.60. Additionally, ORTX Total Debt to Total Capital is recorded at 24.58, with Total Debt to Total Assets ending up at 20.70. Long-Term Debt to Equity for the company is recorded at 24.87, with the Long-Term Debt to Total Capital now at 18.75.
Reflecting on the efficiency of the workforce at the company, Orchard Therapeutics plc [ORTX] managed to generate an average of -$683,756 per employee. Receivables Turnover for the company is 0.15 with a Total Asset Turnover recorded at a value of 0.01.Orchard Therapeutics plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.70 and a Current Ratio set at 6.80.
Insider trade positions for Orchard Therapeutics plc [ORTX]
There are presently around $324 million, or 65.90% of ORTX stock, in the hands of institutional investors. The top three institutional holders of ORTX stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 12,315,213, which is approximately 0% of the company’s market cap and around 0.30% of the total institutional ownership; ARTISAN PARTNERS LIMITED PARTNERSHIP, holding 10,643,790 shares of the stock with an approximate value of $44.17 million in ORTX stocks shares; and FMR LLC, currently with $35.74 million in ORTX stock with ownership of nearly -29.672% of the company’s market capitalization.
Positions in Orchard Therapeutics plc stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 45 institutional holders increased their position in Orchard Therapeutics plc [NASDAQ:ORTX] by around 27,574,346 shares. Additionally, 34 investors decreased positions by around 9,441,191 shares, while 13 investors held positions by with 41,001,069 shares. The mentioned changes placed institutional holdings at 78,016,606 shares, according to the latest SEC report filing. ORTX stock had 18 new institutional investments in for a total of 14,549,783 shares, while 13 institutional investors sold positions of 3,191,844 shares during the same period.